Latest:
Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer
Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Judi Payne, BSM
Latest:
Assess, Plan, and Be Flexible for MIPS
Under the new Quality Payment Program, most providers, including community oncologists, are expected to fall under Merit-based Incentive Payment System for the 2017 performance year. With careful analysis and planning, community oncology practices can choose measures that are a good fit and hold the most opportunity for revenue enhancement.
Judith Trotman, MBChB, FRACP
Judith Trotman, MBChB, FRACP, is a clinical professor of medicine at Concord Clinical School, as well as director of the Clinical Research Unit in the Haematology Department at Concord Hospital
Latest:
Career Development and Mentorship in Medicine
Ann LaCasce, MD, MMSc; and Judith Trotman, MBChB, FRACP, discuss career development and mentorship in medicine.
Judith Trotman, MD
Latest:
Dr. Trotman on BGB-3111 in Patients With Waldenstrom's Macroglobulinemia
Judith Trotman, MD, clinical associate professor, medicine, Concord Clinical School, The University of Sydney, discusses results of a trial investigating BGB-3111 in patients with Waldenstrom’s macroglobulinemia.
Judy C. Boughey, MD, FACS
Latest:
Minimizing Axillary Surgery for Patients With Node-Positive Breast Cancer
As advances in systemic therapy improve our ability to individualize breast cancer treatment, and improve response rates and outcomes, it is important to reevaluate the most appropriate form of local-regional management.
Julia K. Rotow, MD
Latest:
Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC
This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.
Julia R. Mendoza-Perez, PhD
Latest:
Next Steps With Obesity-Related Genes in Patients With RCC
Julia R. Mendoza-Perez, PhD, visiting scientist, Epidemiology, The University of Texas MD Anderson Cancer Center, discusses next steps and research regarding obesity-related genes in patients with renal cell carcinoma (RCC).